Zymeworks Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

ZymeworksDer Gewinn des Unternehmens wird voraussichtlich um 0.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 14% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 7.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -49.6% betragen.

Wichtige Informationen

-6.0%

Wachstumsrate der Gewinne

0.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.6%
Wachstumsrate der Einnahmen	8.2%
Zukünftige Eigenkapitalrendite	-45.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	25 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ZYME - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	139	-75	-86	-66	6
12/31/2025	120	-81	-124	-88	7
12/31/2024	109	-78	-63	-29	7
6/30/2024	63	-113	-96	-91	N/A
3/31/2024	50	-126	-77	-73	N/A
12/31/2023	76	-119	-122	-118	N/A
9/30/2023	462	205	192	195	N/A
6/30/2023	448	186	159	165	N/A
3/31/2023	446	173	108	116	N/A
12/31/2022	412	124	131	144	N/A
9/30/2022	30	-224	-252	-234	N/A
6/30/2022	32	-237	-231	-212	N/A
3/31/2022	28	-240	-224	-207	N/A
12/31/2021	27	-212	-206	-192	N/A
9/30/2021	22	-211	-199	-190	N/A
6/30/2021	21	-223	-161	-155	N/A
3/31/2021	31	-194	-161	-155	N/A
12/31/2020	39	-181	-158	-151	N/A
9/30/2020	25	-215	-147	-140	N/A
6/30/2020	30	-173	-150	-135	N/A
3/31/2020	26	-163	-113	-98	N/A
12/31/2019	30	-145	-96	-82	N/A
9/30/2019	57	-64	-7	5	N/A
6/30/2019	51	-52	-2	3	N/A
3/31/2019	65	-29	17	20	N/A
12/31/2018	53	-37	21	24	N/A
9/30/2018	74	-13	10	13	N/A
6/30/2018	72	-11	12	14	N/A
3/31/2018	52	-16	N/A	-5	N/A
12/31/2017	52	-11	N/A	0	N/A
9/30/2017	4	-55	N/A	-47	N/A
6/30/2017	6	-51	N/A	-50	N/A
3/31/2017	11	-47	N/A	-41	N/A
12/31/2016	11	-34	N/A	-35	N/A
9/30/2016	10	-30	N/A	-32	N/A
12/31/2015	10	-19	N/A	-22	N/A
12/31/2014	2	-13	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ZYME wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ZYME wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ZYME wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ZYMEDie Einnahmen des Unternehmens (8.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.6% pro Jahr).

Hohe Wachstumseinnahmen: ZYMEDie Einnahmen des Unternehmens (14% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ZYME wird voraussichtlich in 3 Jahren unrentabel sein.

Zymeworks Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 14%

Consensus EPS estimates upgraded to US$0.88 loss, revenue downgraded

Consensus EPS estimates fall by 10%

Consensus revenue estimates increase by 51%, EPS downgraded

No longer forecast to breakeven

Price target increased by 8.4% to US$13.73

Recent updates

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Consensus revenue estimates increase by 14%

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc. (NasdaqGS:ZYME) announces an Equity Buyback for $60 million worth of its shares.

Zymeworks Inc. Announces the Appointment of Leone Patterson as Executive Vice President and Chief Business Officer, Effective September 1, 2024

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks Inc. to Report Q2, 2024 Results on Aug 01, 2024

Zymeworks: A Somewhat Complicated Story

Zymeworks Inc. Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Zymeworks Inc. to Report Q1, 2024 Results on May 02, 2024

Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President

Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024

Consensus EPS estimates upgraded to US$0.88 loss, revenue downgraded

New minor risk - Profitability

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

High number of new directors

Zymeworks Inc. to Report Q4, 2023 Results on Mar 06, 2024

Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

CEO & Chairman of the Board notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Zymeworks Inc. Announces Changes to its Board

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zymeworks Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zymeworks Inc., Annual General Meeting, Dec 07, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Zymeworks Inc. Appoints Carlos E. Campoy to the Board of Directors, Effective from June 30, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Investor sentiment deteriorates as stock falls 16%

Zymeworks Inc. Announces Executive Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 16%

Insufficient new directors

Consensus EPS estimates fall by 10%

Consensus revenue estimates increase by 51%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Price target increased by 8.4% to US$13.73

Consensus revenue estimates increase by 18%

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Consensus revenue estimates increase by 19%

Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer

Insider recently sold US$8.0m worth of stock

Consensus revenue estimates fall by 12%

Zymeworks Inc. Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

Consensus revenue estimates fall by 11%

Zymeworks Inc. Announces New Clinical Data for Zanidatamab in Her2+ /Hr+ Metastatic Breast Cancer Presented At 2022 Sabcs

Zymeworks Inc., Annual General Meeting, Dec 16, 2022

Consensus revenue estimates increase by 25%

Price target decreased to US$12.14

Consensus revenue estimates increase by 34%

Third quarter 2022 earnings released: US$0.72 loss per share (vs US$1.17 loss in 3Q 2021)

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Price target decreased to US$16.35

Consensus revenue estimates increase by 246%

Zymeworks Inc. to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$17.98

Zymeworks Inc. Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) At European Society for Medical Oncology Annual Congress

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers